Seattle Genetics, Inc.’s $575 Million Equity Offering


Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering of common stock by Seattle Genetics, Inc. for gross proceeds of $575 million.

Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer.

J.P. Morgan Securities LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint book-running managers on the deal.

Cooley LLP advised Seattle Genetics on the transaction.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Bryan M. Quinn, Daniel Fox and Kimberly Wang. Partner Mario J. Verdolini and associate Eitan Ulmer provided tax advice. Partner Frank J. Azzopardi and associate Jesse L. Hallock provided intellectual property and technology advice.

Involved fees earner: Frank Azzopardi – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Daniel Fox – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Bryan Quinn – Davis Polk & Wardwell; Eitan Ulmer – Davis Polk & Wardwell; Mario Verdolini – Davis Polk & Wardwell; Kimberly Wang – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman Sachs & Co.; J.P. Morgan Securities LLC; SVB Leerink LLC;

Author: Ambrogio Visconti